
Measurement of insulin and C-peptide is not currently recommended for diagnosis and management of diabetes. This is due, in part, to a lack of standardization across laboratories.  To enable comparisons between laboratories, assays must be standardized (ie, traceable to a common reference material).  Ideally, the reference material is traceable to the International System of Units (SI). However, most peptide assays are standardized against World Health Organization (WHO) reference materials that are not SI-traceable (ie, there is uncertainty in the amount of pure material originally weighed).  Furthermore, the reference materials previously used for the standardization of most insulin and C-peptide assays are no longer available.
In a previous study aimed at improving standardization, the investigators developed and validated a multiplexed liquid chromatography tandem mass spectrometry (LC-MS/MS) assay that simultaneously measures intact insulin and C-peptide in patient sera. 1 What was done in this study?
 In this letter, the investigators provide more information about how they characterized peptides that were used to develop the LC-MS/MS assay to enable SI-traceability.
The peptide content of insulin and C-peptide "calibrators" and "controls" was determined by quantitative amino acid analysis.  Calibrators were used to measure the response of the assay to increasing concentrations of peptide. Controls were used to check the accuracy of the assay; different suppliers provided calibrators and controls.  Insulin and C-peptide concentrations in patient samples were determined using the LC-MS/MS assay and immunoassays. Results were compared.
What were the new findings in this study? Quantitative Amino Acid Analysis in Insulin and C-peptide Assays
